老年起病类风湿关节炎在达标治疗策略下风险获益良好且可行
该研究基于Rotterdam早期关节炎队列试验数据,比较了老年起病(EORA)与年轻起病(YORA)类风湿关节炎患者在固定方案达标治疗(T2T)下的2年药物需求与不良事件。结果显示EORA患者DAS44轨迹与YORA相似,bDMARD启用率更低更慢,难治性RA罕见,因不良事件调整治疗的比例相似,提示T2T在EORA中可行且风险获益良好。
要点
- EORA患者DAS44轨迹与YORA相似,持续缓解比例更高但差异无统计学意义。
- EORA患者bDMARD启用率更低更慢(28% vs 38%;HR 0.7,95%CI 0.4-1)。
- EORA与YORA因不良事件调整治疗比例相似(43% vs 47%),D2T-RA罕见。
核心结论
- 在固定药物方案的达标治疗策略下,EORA患者2年风险获益良好,T2T可行且有效,但需个体化管理。
研究设计与样本
- 分析Rotterdam早期关节炎队列试验(多中心随机对照研究)数据,425例RA患者按起病年龄分为EORA(>65岁,98例)和YORA(18-65岁,327例)。
主要发现
- EORA患者男性更多(50% vs 28%),合并症更多(76% vs 49%)。
- DAS44轨迹相似(平均差0.03,95%CI -0.13至0.18),EORA活动性疾病OR 0.8(95%CI 0.4-1.5),持续缓解OR 1.5(95%CI 0.6-3.4)。
- EORA的bDMARD启用率更低更慢(28% vs 38%;HR 0.7,95%CI 0.4-1),首个bDMARD生存率和GC使用相当。
- D2T-RA罕见(EORA 2% vs YORA 6%),因不良事件调整治疗比例相似(43% vs 47%)。
临床怎么用
- 对EORA患者可考虑采用T2T策略,同时注意其合并症较多并实施个体化管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare 2-year pharmacotherapy needs and adverse events (AEs) profiles between patients with elderly-onset rheumatoid arthritis (EORA) and young-onset RA (YORA) under a treat-to-target (T2T) strategy with a fixed medication protocol. METHODS: Data from the treatment in the Rotterdam Early Arthritis cohort trial, a multicentre randomised controlled study, were analysed. Patients with RA (1987/2010 criteria) were classified as EORA (>65 years) or YORA (18-65 years). Disease Activity Score based on 44 swollen and 53 tender joint counts (DAS44) trajectories, active disease and sustained remission were assessed using mixed-effects models. Protocol-guided disease-modifying antirheumatic drug (DMARD) and glucocorticoid (GC) use, difficult-to-treat (D2T) RA prevalence and AEs were evaluated descriptively. Cox proportional hazards models examined time to first biologic (b)DMARD initiation, bDMARD survival and DMARD-free remission. RESULTS: Among 425 patients with RA, 98 (23%) had EORA (mean age 73 years, SD 5) and 327 (77%) had YORA (mean age 48 years, SD 11). Patients with EORA were more often male (50% vs 28%) and had more comorbidities (76% vs 49%). DAS44 trajectories were similar (mean difference 0.03, 95% CI -0.13 to 0.18), but EORA had less often active disease (OR 0.8, 95% CI 0.4 to 1.5) and more often sustained remission (OR 1.5, 95% CI 0.6 to 3.4). bDMARD initiation rate was lower and slower in EORA than YORA (28% vs 38%; HR 0.7, 95% CI 0.4 to 1). First bDMARD survival and GC use were comparable. D2T-RA was rare (EORA 2% vs YORA 6%) and treatment adjustments due to AEs were similar (43% vs 47%). CONCLUSION: A T2T approach is feasible and effective in EORA, given its reassuring risk-benefit profile, while recognising the need for individualised management.
引用
- Dag HH, van Onna MGB, Dolhain RJEM, et al. Treat-to-target strategies are feasible in elderly-onset rheumatoid arthritis given its reassuring risk-benefit profile. RMD Open. 2026. PMID: 42399075. doi:10.1136/rmdopen-2026-007055
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。